Further Vyvanse shortages forecast

Takeda Pharmaceuticals Australia warns that a fourth strength of its ADHD medication, Vyvanse, will be in short supply   Worldwide shortages of Takeda’s Vyvanse (lisdexamfetamine dimesilate) products are expected to continue until late April, as a result of manufacturing issues, the company says.  In an update issued by the Therapeutic Goods Administration (TGA) today (18

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacies to support at home palliative care
Next Hospital walkout over parking fee hike